Park SY - Search Results

1

Standardized Pathology Report for Breast Cancer.

Cho SY, Park SY, Bae YK, Kim JY, Kim EK, Kim WG, Kwon Y, Lee A, Lee HJ, Lee JS, Park JY, Gong G, Yoon HK. Cho SY, et al. Among authors: park jy, park sy. J Breast Cancer. 2021 Feb;24(1):1-21. doi: 10.4048/jbc.2021.24.e5. J Breast Cancer. 2021. PMID: 33634617 Free PMC article. Review.

2

Feasibility of sentinel lymph node biopsy in breast cancer patients with initial axillary lymph node metastasis after primary systemic therapy.

Kang E, Chung IY, Han SA, Kim SM, Jang M, Lyou CY, Park SY, Kim JH, Kim YJ, Kim SW. Kang E, et al. Among authors: park sy. J Breast Cancer. 2011 Jun;14(2):147-52. doi: 10.4048/jbc.2011.14.2.147. Epub 2011 Jun 18. J Breast Cancer. 2011. PMID: 21847411 Free PMC article.

3

Reply to 'Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance'.

Lee HJ, Park SY. Lee HJ, et al. Among authors: park sy. Mod Pathol. 2013 Apr;26(4):610-1. doi: 10.1038/modpathol.2013.38. Mod Pathol. 2013. PMID: 23542524 Free article. No abstract available.

4

Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.

Choi Y, Lee HJ, Jang MH, Gwak JM, Lee KS, Kim EJ, Kim HJ, Lee HE, Park SY. Choi Y, et al. Among authors: park sy. Hum Pathol. 2013 Nov;44(11):2581-9. doi: 10.1016/j.humpath.2013.07.003. Epub 2013 Sep 20. Hum Pathol. 2013. PMID: 24055090

5

Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.

Lee HJ, Seo AN, Park SY, Kim JY, Park JY, Yu JH, Ahn JH, Gong G. Lee HJ, et al. Among authors: park jy, park sy. Ann Surg Oncol. 2014 May;21(5):1561-8. doi: 10.1245/s10434-013-3456-x. Epub 2014 Jan 3. Ann Surg Oncol. 2014. PMID: 24385208

6

High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.

Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ, Kim YJ, Kim JH, Kang E, Kim SW, Kim IA, Park SY. Park HS, et al. Among authors: park sy. Mod Pathol. 2014 Sep;27(9):1212-22. doi: 10.1038/modpathol.2013.251. Epub 2014 Jan 10. Mod Pathol. 2014. PMID: 24406864 Free article.

7

Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.

Lee HJ, Park IA, Park SY, Seo AN, Lim B, Chai Y, Song IH, Kim NE, Kim JY, Yu JH, Ahn JH, Gong G. Lee HJ, et al. Among authors: park ia, park sy. Breast Cancer Res Treat. 2014 Jun;145(3):615-23. doi: 10.1007/s10549-014-2983-x. Epub 2014 May 13. Breast Cancer Res Treat. 2014. PMID: 24820412

8

MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.

Gwak JM, Kim HJ, Kim EJ, Chung YR, Yun S, Seo AN, Lee HJ, Park SY. Gwak JM, et al. Among authors: park sy. Breast Cancer Res Treat. 2014 Aug;147(1):39-49. doi: 10.1007/s10549-014-3069-5. Epub 2014 Aug 3. Breast Cancer Res Treat. 2014. PMID: 25086633

9

HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.

Lee HJ, Seo AN, Kim EJ, Jang MH, Suh KJ, Ryu HS, Kim YJ, Kim JH, Im SA, Gong G, Jung KH, Park IA, Park SY. Lee HJ, et al. Among authors: park ia, park sy. Am J Clin Pathol. 2014 Dec;142(6):755-66. doi: 10.1309/AJCPIRL4GUVGK3YX. Am J Clin Pathol. 2014. PMID: 25389328

10

Outcomes and recurrence patterns according to breast cancer subtypes in Korean women.

Lee Y, Kang E, Lee AS, Baek H, Kim EK, Park SY, Kim JH, Kim YJ, Kim SH, Kim IA, Eom KY, Kim SW. Lee Y, et al. Among authors: park sy. Breast Cancer Res Treat. 2015 May;151(1):183-90. doi: 10.1007/s10549-015-3390-7. Epub 2015 Apr 17. Breast Cancer Res Treat. 2015. PMID: 25893592

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,702 results

Search Page